MEA Wearable Injectors Market

MEA Wearable Injectors Market Size (2023 to 2028)

The size of the Middle East and Africa wearable injectors market is projected to be growing at a healthy CAGR from 2023 to 2028.

The increasing prevalence of chronic medical conditions and increasing geriatric population, along with technological advancements of drug delivery injectors around the world, are expected to drive the progress of this market in the near future. According to data collected by the Organization for Economic Co-operation and Development (OECD), around 33% of the total population in OECD countries (including Israel and Turkey) people aged 15 and over suffered from two or more chronic conditions.

Additionally, the ability of wearable injectors to deliver new formulations with higher volume and viscosity can dramatically improve the patient experience, which in turn is expected to drive market growth for years to come. The market's growth can also be attributed to factors such as the continued expansion of research for the development of biologics and favorable reimbursement policies for wearable injectors in major economic regions such as the UAE and Saudi Arabia.

In addition, the favorable repayment scenario, especially in developed countries, is expected to drive the growth of the target market during the projected period. Another factor that is expected to support the market's growth during the analyzed period is manufacturers' introduction of disruptive technology products, intending to gain a competitive advantage. In addition, favorable government investments in healthcare and increasing demand for minimally invasive devices are driving the MEA wearable injectors market growth.

However, the presence and preference for conventional drug delivery methods are expected to restrain the growth of the MEA wearable injectors market during the forecast period. Besides, the adverse recovery scenario, especially in developing countries, is another factor that is expected to limit the growth of the MEA wearable injectors market.

Impact of COVID-19 on the MEA wearable injectors market:

According to the World Health Organization (WHO), the burden of chronic disease is expected to reach 60% by 2025. Almost half of the deaths were due to cardiovascular disease, obesity, and diabetes. The existing COVID-19 pandemic has made people with chronic diseases vulnerable; thus, the market for wearable injectors is blooming as they reduce parenteral administration, frequent dosing, and repeated visits to the hospital. Therefore, many companies are focusing on developing advanced therapeutic delivery solutions to overcome adverse events. This has resulted in lower healthcare costs and better medication adherence.

This research report on the MEA wearable injectors market has been segmented and sub-segmented into the following categories:

By Type:

• On-body
• Off-body

By Technology:

• Spring-based
• Motor-driven
• Rotary Pump
• Expanding Battery
• Others

By Application:

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Autoimmune Diseases
• Others

By End-use:

• Hospitals
• Clinics
• Home Care
• Others

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the Middle East and Africa regional markets are estimated to have a moderate growth rate during the forecast period. Middle East is expected to take first place in the MEA wearable injectors market. The growth of the market in this region is attributed to the increasing prevalence of chronic diseases, the availability of funds for research, and the increase in healthcare spending. According to a report published by the NSD Alliance, 1/5 of the Arab population over 15 suffers from a chronic disease.

Saudi Arabia is expected to be the fastest-growing market region due to its huge patient population, continuously developing economy, increasing prevalence of chronic diseases such as diabetes, cardiovascular disease, and increased public funds for the health sector. According to a study published in the Journal of Tropical Biomedicine in 2018, it has been estimated that around 120 million diabetic patients reside in the MEA region, of which more than 85% have type 2 diabetes.

In contrast, the African region has the lowest market share. The majority of the market in this region is expected to be in the hands of the Northern Africa region due to the well-developed healthcare industry and increasing government initiatives for the healthcare industry.

KEY MARKET PLAYERS:

Amgen, Becton, and Dickinson and Company, Medtronic, Valeritas, Inc, Insulet Corporation, Gerresheimer AG (Sensile Medical), Tandem Diabetes Care, SteadyMed Therapeutics, Inc., United Therapeutics Corporation, Sensile Medical AG, Zealand Pharma A/S (Valeritas, Inc.), West Pharmaceutical Services, Inc., SteadyMed Therapeutics, F. Hoffmann-La Roche Ltd, Ypsomed, Johnson & Johnson, Dexcom, Inc., Enable Injections, CeQur SA, Sensile Medicals and Bespak are playing a noteworthy role in the MEA wearable injectors market.